Alkem Laboratories

₹3408.5 -36.1 | 1%

WEBSITE BSE:539523 NSE : ALKEM 09 Jun, 12:27

Market Cap ₹40838 Cr.

Stock P/E 41.4

P/B 4.5

Current Price ₹3408.5

Book Value ₹ 756.5

Face Value 2

52W High ₹3624.8

Dividend Yield 1.46%

52W Low ₹ 2835.1

Edit Ratio

Alkem Laboratories Research see more...

Overview Inc. Year: 1973Industry: Pharmaceuticals & Drugs

Alkem Laboratories Limited is a pharmaceutical agency. The Company is engaged inside the development, manufacture and sale of pharmaceutical and neutraceutical products. The Company operates via 2 segments: pharmaceutical and investing. The Company produces generics,generic drugs, APIs and neutraceuticals, which it markets in India and about 50 international locations across the world. The Company offers numerous products, which include CLAVAM 375, CLAVAM BID DRY SYRUP, CLAVAM INJ 300MG, FREEAIR NASAL SPRAY, PAN 40MG INJECTION (VIAL), PAN/40MG TABLETS, PROWEL DRY SYRUP (30ML), TAXCLAV 100 DT TABLETS, SATROGYL O DRY SYRUP, XONE/500MG VAIL, MEROSURE KIT 500, MEROSURE 500 MG and ZADONASE, amongst others. The Company has approximately 16 production facilities, of which 14 manufacturing facilities are at geographically different places in India and within the United States.

Alkem Laboratories Share Price

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Alkem Laboratories Quarterly Results

#(Fig in Cr.)	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023
Net Sales	2318	2192	2731	2800	2619	2484	2576	3079	3041	2903
Other Income	96	46	47	42	54	21	51	51	45	69
Total Income	2414	2238	2778	2842	2673	2504	2628	3130	3086	2971
Total Expenditure	1789	1901	2139	2176	2121	2147	2373	2625	2442	2549
Operating Profit	626	337	640	666	552	358	255	505	644	422
Interest	13	11	13	12	11	17	27	25	27	29
Depreciation	69	69	71	73	77	83	76	77	78	78
Exceptional Income / Expenses	0	0	0	0	0	-15	0	0	0	-103
Profit Before Tax	543	258	556	582	464	243	152	402	539	212
Provision for Tax	80	9	76	23	-69	134	20	55	79	144
Profit After Tax	464	249	480	559	533	108	131	348	460	68
Adjustments	-13	-9	-12	-14	-8	-1	-4	-17	-5	3
Profit After Adjustments	451	240	468	544	526	108	128	331	455	71
Adjusted Earnings Per Share	37.7	20.1	39.2	45.5	44	9	10.7	27.7	38	5.9

Alkem Laboratories Profit & Loss

#(Fig in Cr.)	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	TTM
Net Sales	2016	2495	3126	3743	4925	5688	6392	7357	8344	8865	10634	11599
Other Income	145	167	165	181	240	112	115	88	104	233	163	216
Total Income	2161	2662	3291	3924	5165	5800	6507	7445	8449	9098	10797	11815
Total Expenditure	1640	2133	2716	3322	4072	4689	5383	6242	6871	6923	8581	9989
Operating Profit	520	530	575	603	1093	1111	1124	1202	1578	2176	2216	1826
Interest	58	88	93	81	71	45	55	55	65	59	52	108
Depreciation	29	40	52	71	93	101	143	193	253	275	304	309
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	-15	-103
Profit Before Tax	433	402	430	451	928	965	926	955	1260	1842	1844	1305
Provision for Tax	28	18	-5	59	176	60	288	181	110	224	164	298
Profit After Tax	406	384	435	392	752	905	638	774	1149	1618	1680	1007
Adjustments	1	0	0	0	-11	-13	-7	-13	-22	-33	-35	-23
Profit After Adjustments	407	384	435	392	742	892	631	761	1127	1585	1646	985
Adjusted Earnings Per Share	34	32.1	36.4	32.8	62	74.6	52.8	63.6	94.3	132.6	137.7	82.3

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	20%	13%	13%	18%
Operating Profit CAGR	2%	23%	15%	16%
PAT CAGR	4%	29%	13%	15%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	9%	12%	12%	NA%
ROE Average	21%	22%	19%	20%
ROCE Average	19%	20%	19%	18%

Alkem Laboratories Balance Sheet

#(Fig in Cr.)	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Shareholder's Funds	1820	2177	2585	2999	3692	4468	4864	5439	6161	7377	8638
Minority's Interest	0	0	0	86	95	115	122	133	148	181	209
Borrowings	309	256	232	33	123	182	131	231	74	28	9
Other Non-Current Liabilities	216	106	92	167	-430	-582	-489	-520	-614	-779	-902
Total Current Liabilities	1121	1732	1403	2006	1538	1690	2383	2218	3245	3604	4805
Total Liabilities	3466	4271	4311	5291	5018	5872	7010	7501	9013	10411	12760
Fixed Assets	919	1072	1170	1374	1450	1797	2284	2530	2908	2793	2902
Other Non-Current Assets	1234	1042	1539	1579	800	1158	713	754	599	690	1423
Total Current Assets	1312	2156	1602	2338	2769	2917	4013	4204	5506	6923	8434
Total Assets	3466	4271	4311	5291	5018	5872	7010	7501	9013	10411	12760

Alkem Laboratories Cash Flow

#(Fig in Cr.)	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Opening Cash & Cash Equivalents	124	26	57	101	124	127	167	167	249	176	174
Cash Flow from Operating Activities	159	78	290	325	726	471	266	780	585	1265	1111
Cash Flow from Investing Activities	-248	-404	350	-237	202	-286	-357	-316	-741	-999	-1435
Cash Flow from Financing Activities	-11	356	-600	-52	-927	-138	85	-379	79	-272	380
Net Cash Inflow / Outflow	-100	30	41	37	1	47	-7	84	-77	-5	55
Closing Cash & Cash Equivalent	26	57	101	140	127	167	167	249	176	174	232

Alkem Laboratories Ratios

#	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022
Earnings Per Share (Rs)	33.99	32.09	36.4	32.76	62.03	74.62	52.78	63.61	94.28	132.58	137.65
CEPS(Rs)	36.36	35.4	40.77	38.69	70.73	84.14	65.37	80.87	117.28	158.29	165.98
DPS(Rs)	4	4	4	4	12.7	15	13	16	25	30	34
Book NAV/Share(Rs)	152.18	182.05	216.13	250.86	308.82	373.67	406.76	454.86	515.21	616.95	722.48
Core EBITDA Margin(%)	18.12	14.07	12.66	10.93	16.9	17.07	11.76	10.41	11.89	14.82	13.44
EBIT Margin(%)	23.73	19.02	16.15	13.78	19.8	17.25	11.43	9.42	10.69	14.5	12.42
Pre Tax Margin(%)	20.92	15.59	13.28	11.68	18.39	16.48	10.79	8.91	10.16	14.05	12.07
PAT Margin (%)	19.6	14.9	13.44	10.15	14.9	15.46	7.44	7.22	9.27	12.34	11
Cash Profit Margin (%)	21	16.44	15.06	11.98	16.75	17.19	9.1	9.03	11.31	14.43	12.99
ROA(%)	12.85	9.92	10.14	8.16	14.59	16.61	9.91	10.66	13.92	16.66	14.5
ROE(%)	24.95	19.19	18.28	14.03	22.48	22.18	13.69	15.02	19.82	23.91	20.99
ROCE(%)	19.02	14.96	14.06	13.27	23.1	21.31	17.86	16.49	18.71	22.56	18.69
Receivable days	36.8	40.02	38.62	42.27	39.57	39.95	38.15	39.69	42.66	45.33	41.72
Inventory Days	56.02	66.53	66.19	66.41	61.23	65.96	56.31	50.14	48.86	57.51	63.54
Payable days	125.4	118.68	92.7	96.89	117.1	133.45	156.37	135.69	118.18	118.18	114.79
PER(x)	0	0	0	0	22.03	29.58	37.46	27.54	24.7	20.91	26.28
Price/Book(x)	0	0	0	0	4.42	5.91	4.86	3.85	4.52	4.49	5.01
Dividend Yield(%)	0	0	0	0	0.93	0.68	0.66	0.91	1.07	1.08	0.94
EV/Net Sales(x)	0.25	0.23	0.3	0.14	3.29	4.68	3.76	2.88	3.4	3.71	4.07
EV/Core EBITDA(x)	0.97	1.07	1.62	0.89	14.83	23.98	21.4	17.65	17.98	15.1	19.52
Net Sales Growth(%)	19.21	23.79	25.28	19.75	31.56	15.49	12.38	15.1	13.42	6.24	19.96
EBIT Growth(%)	31.91	-0.33	6.78	1.7	87.93	1.01	-2.82	2.85	31.27	43.49	-0.23
PAT Growth(%)	37.21	-5.47	13.47	-10.05	92.1	20.27	-29.43	21.18	48.56	40.76	3.87
EPS Growth(%)	37.54	-5.59	13.42	-10.01	89.38	20.29	-29.27	20.54	48.2	40.63	3.82
Debt/Equity(x)	0.55	0.71	0.44	0.44	0.18	0.15	0.21	0.17	0.26	0.23	0.3
Current Ratio(x)	1.17	1.25	1.14	1.17	1.8	1.73	1.68	1.9	1.7	1.92	1.76
Quick Ratio(x)	0.83	0.93	0.7	0.77	1.21	1.01	1.08	1.22	1.14	1.28	1.13
Interest Cover(x)	8.46	5.55	5.62	6.56	14.03	22.36	17.74	18.48	20.36	32.26	36.22
Total Debt/Mcap(x)	0	0	0	0	0.04	0.02	0.04	0.05	0.06	0.05	0.06

Alkem Laboratories Shareholding Pattern

#	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023
Promoter	62.43	60.16	58.84	58.84	57.13	57.13	57.14	57.16	57.16	57.16
FII	4.08	4.42	4.5	5.33	5.4	5.41	5.67	4.46	4.41	4.44
DII	12.96	13.2	14.49	13.99	13.94	14.14	14.1	15.74	16.44	16.69
Public	20.53	22.22	22.17	21.84	23.53	23.32	23.09	22.65	21.99	21.7
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023
Promoter	7.46	7.19	7.04	7.04	6.83	6.83	6.83	6.83	6.83	6.83
FII	0.49	0.53	0.54	0.64	0.65	0.65	0.68	0.53	0.53	0.53
DII	1.55	1.58	1.73	1.67	1.67	1.69	1.69	1.88	1.97	2
Public	2.45	2.66	2.65	2.61	2.81	2.79	2.76	2.71	2.63	2.59
Others	0	0	0	0	0	0	0	0	0	0
Total	11.96	11.96	11.96	11.96	11.96	11.96	11.96	11.96	11.96	11.96

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 22%
Debtor days have improved from 118.18 to 114.79days.
Company has reduced debt.
Company is almost debt free.

Cons

Stock is trading at 4.5 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.